Entity

Time filter

Source Type

Boston, MA, United States

Background: The discovery of sodium-glucose co-transporter 2 (SGLT2) inhibitors, with a novel mechanism independent of insulin secretion or sensitization, bring about a new therapeutic approach to the management of type 2 diabetes mellitus. The aim of this meta-analysis was to evaluate the safety and efficacy of SGLT2 inhibitors at different doses in randomized double blind clinical trials.Methods: This meta-analysis was conducted by including randomized double-blind controlled trials of SGLT2 inhibitors in patients with type 2 diabetes irrespective of their antidiabetic drug exposure history but with an inadequate glycemic control. All the effect sizes were computed using the random effects model. Standardized mean differences (SMDs) and odds ratios (OR) were computed for continuous and dichotomous variables, respectively. Additional analyses like sensitivity analysis, subgroup analysis and meta-regression were also performed.Results: The pooled analyses demonstrated a significant reduction in mean changes in Hemoglobin A1c (HbA1c) (SMD = -0.78%, 95% CI, -0.87 to -0.69), fasting plasma glucose (FPG) (SMD = -0.70 mg/dl, 95% CI, -0.79 to -0.61), body weight (overall SMD = -0.59 kg, 95% CI, -0.65 to -0.52) and blood pressure from baseline with SGLT2 inhibitors based therapy. Consistently a significant number of patients treated with SGLT2 inhibitors achieved HbA1c < 7% (OR = 2.09, 95% CI, 1.77 to 2.46). SGLT2 inhibitors based therapy was associated with adverse events like genital and urinary tract infections.Conclusion: All studied doses of SGLT2 inhibitors, either as monotherapy or in combination with other antidiabetic agents, consistently improved glycemic control in patients with type 2 diabetes. However, a small percentage of patients suffer from genital and urinary tract infections. © 2013 Berhan and Barker; licensee BioMed Central Ltd. Source


Background: Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD). It is a selective serotonin (5-HT) 3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of serotonin transporters. The objective of this meta-analysis was to evaluate the efficacy and safety of vortioxetine in adults with MDD.Methods: A literature search was conducted in the databases of PubMed, EMBASE, Cochrane library and HINARI. The meta-analysis was conducted by including randomized controlled trials that assessed the efficacy and safety of vortioxetine in adult patients with MDD. Using the random effects model, which assumes individual studies are estimating different treatment effects, the efficacy and safety of vortioxetine was determined by weighted mean differences (WMDs) and odds ratios (ORs). The findings were considered as statistically significant when the 95% CI of WMDs and ORs did not include 0 and 1, respectively. Heterogeneity testing, meta-regression and sensitivity analysis were also performed.Results: During the initial literature search about 151 publications were identified. Based on the predetermined inclusion criteria, 7 randomized controlled trials were included. The pooled analysis demonstrated a statistically significant reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline among patients who were on vortioxetine (WMD = -3.92; 95% CI, -5.258 to -2.581). Furthermore, a statistically significant number of patients with MDD who were on vortioxetine have achieved a greater than or equal to 50% reduction in depression symptoms from baseline. However, a significant number of patients who were on vortioxetine therapy reported more adverse events than patients who were on placebo (overall OR = 1.21; 95% CI, 1.06 to 1.38).Conclusions: Therapy with vortioxetine was significantly associated with reduction in depression symptoms from baseline compared to placebo. Nevertheless, a significant number of patients who were on vortioxetine therapy have reported more adverse events. © 2014 Berhan and Barker; licensee BioMed Central Ltd. Source


Patent
Iron Mountain | Date: 2010-05-28

Instead of adding resources into a folder by specifying a list of identifiers, client applications add resources to a folder by specifying a search query that matches the resources to be added. The virtual folder is, therefore, a collection of search queries rather than a collection of resource identifiers. This allows the data archive systems to easily store folder information in a database. A client application can then search by specifying the folder as its search criteria to list all content associated with the folder. Additionally, to ensure that the list of results associated with a particular query does not change after the query is added into a folder, the data archive system also captures generation information associated with the particular query (i.e., the iteration of the search indexes at the time the query is received) and stores the generation information with the query as part of the folder.


Patent
Iron Mountain | Date: 2012-11-28

An animal tracking device removably attachable to an arrow and including an antenna, a controller, a battery for powering the controller, a housing for housing the antenna, controller, and battery, and an animal attachment component fixed to the housing. The controller may transmit wireless signals to a receiver via the antenna. The housing may have a first and second portion pivotally attached at a first joint. The first and second portions may also meet, but not attach with each other, at a second joint in a closed position. The first and second portions may pivot between the closed position and an open position about the first joint, may be naturally biased in the open position, and may be detachably attached in the closed position to the arrow shaft. The animal attachment component may attach to an animal shot by the arrow, forcing the housing away from the arrow.


Patent
Iron Mountain | Date: 2013-06-05

A technique for organizing pathology samples includes sorting the samples into bins defined at different physical locations of a sorting apparatus, based on a set of designations applied to the samples. With such an arrangement, unorganized pathology samples may be grouped so that all the same accession numbers are grouped together for efficient filing or re-filing with reduced error. An apparatus suitable for use according to this technique includes a support structure and multiple dividers defining multiple sets of bins on the apparatus. A different set of bins is provided on the apparatus for each of the set of designations applied to the samples.

Discover hidden collaborations